“OurPharma produces critical, high-quality medications that are essential to the health and well-being of our patients,” said Dr. Peter Kohler, CEO, OurPharma. Through quality-driven initiatives, OurPharma is redefining the 503B outsourcing industry.
Meeting the needs of healthcare organizations that want to take their 503B pharmacy to a new level of care and safety can team up with OurPharma. They offer a portfolio of critically needed ready-to-administer sterile injectables, intravenous fluids, and medication cassettes.
When outsourcing compounding medicines, pharmacy management wants a vendor with expertise in sterile pharmaceutical manufacturing and repackaging, ensuring transparency with all processes.
OurPharma tests all products by an independent, FDA-regulated analytics lab. They bring an extensive internal drug diversion program and expiration dating backed by extended stability data. With ongoing product development to improve pharmacy operations, this 503B vendor puts the provider and patient needs first.
This post is related to:
Admixture Compounding Services (503B Outsourcing Facilities)